Abstract
Among the GTPase family members, guanylate-binding protein-1 (GBP-1) is the most thoroughly studied member in a plethora of human cancers. GBP-2, on the other hand, remains limitedly studied. We wonder how GBP-2 participates in colorectal carcinoma (CRC) as well as the paclitaxel (PTX)-resistance of CRC. In this study, the authors are determined to dig into the role that GBP-2 plays in the sensitivity of CRC to PTX, therefore, possibly indicating a promising gene therapy target for CRC. Forced expression of GBP-2 gene was done by plasmid transfection. Reverse transcriptase-polymerase chain reaction and immunoblot were conducted to detect the expression of GBP-2 messenger RNA (mRNA) and protein, respectively. Colony foci formation assay, transwell invasion assay, and flow cytofluorometry were done to determine the proliferation, invasion, and apoptosis of PTX-resistant and PTX-sensitive CRC cell lines, respectively. The level of GBP-2 mRNA and protein in PTX-resistant CRC cell lines was significantly lower than in nonresistant cell lines. Forced exogenous expression of GBP-2 in PTX-resistant CRC cell lines resulted in more sensitivity to PTX because of the demonstration of less cell proliferation, invasion, and more apoptosis. Wnt signaling was suppressed when GBP-2 was upregulated by transfection of GBP-2 overexpression plasmids, and Wnt signaling did not affect GBP-2 expression. GBP-2 upregulation could enhance the killing effect of PTX in both PTX-sensitive CRC cells and PTX-resistant CRC cells by suppressing Wnt signaling.